Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 110

1.

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.

Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, Reck M, Mok T, Lam S, Shames DS, Liu J, Ding B, Lopez-Chavez A, Kabbinavar F, Lin W, Sandler A, Liu SV; IMpower133 Study Group.

N Engl J Med. 2018 Dec 6;379(23):2220-2229. doi: 10.1056/NEJMoa1809064. Epub 2018 Sep 25.

PMID:
30280641
2.

Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study.

Barlesi F, Vansteenkiste J, Spigel D, Ishii H, Garassino M, de Marinis F, Özgüroğlu M, Szczesna A, Polychronis A, Uslu R, Krzakowski M, Lee JS, Calabrò L, Arén Frontera O, Ellers-Lenz B, Bajars M, Ruisi M, Park K.

Lancet Oncol. 2018 Nov;19(11):1468-1479. doi: 10.1016/S1470-2045(18)30673-9. Epub 2018 Sep 24. Erratum in: Lancet Oncol. 2018 Nov;19(11):e581.

PMID:
30262187
3.

A phase 2, open-label, multi-center study of amuvatinib in combination with platinum etoposide chemotherapy in platinum-refractory small cell lung cancer patients.

Byers LA, Horn L, Ghandi J, Kloecker G, Owonikoko T, Waqar SN, Krzakowski M, Cardnell RJ, Fujimoto J, Taverna P, Azab M, Camidge DR.

Oncotarget. 2017 Aug 3;8(46):81441-81454. doi: 10.18632/oncotarget.19888. eCollection 2017 Oct 6.

4.

Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 Study.

Gottfried M, Bennouna J, Bondarenko I, Douillard JY, Heigener DF, Krzakowski M, Mellemgaard A, Novello S, Orlov S, Summers Y, von Pawel J, Stöhr J, Kaiser R, Reck M.

Target Oncol. 2017 Aug;12(4):475-485. doi: 10.1007/s11523-017-0517-2.

PMID:
28702806
5.

Recommendations of the Fertility Preservation Working Group in Oncological, Hematological and Other Patients Treated With Gonadotoxic Therapies "ONCOFERTILITY" (GROF) of the Polish Society of Oncological Gynecology.

Jach R, Pabian W, Spaczyński R, Szamatowicz J, Zbroch T, Knapp P, Smolarczyk R, Kolawa W, Bodnar L, Kurzawa R, Zawirska D, Krzakowski M, Radowicki S, Fijuth J, Wielgoś M, Wysocki P, Kozioł K, Zalewski K, Warzocha K, Hałaburda K, Rdwan M, Radwan P, Jabłoński MJ, Kojs Z, Wołczyński S, Pawelczyk L, Kluz T, Lukaszuk KK.

J Adolesc Young Adult Oncol. 2017 Sep;6(3):388-395. doi: 10.1089/jayao.2017.0039. Epub 2017 Jun 28. No abstract available.

PMID:
28657411
6.

Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non-small cell lung cancer in patients with common and rare EGFR gene mutations.

Krawczyk P, Kowalski DM, Ramlau R, Kalinka-Warzocha E, Winiarczyk K, Stencel K, Powrózek T, Reszka K, Wojas-Krawczyk K, Bryl M, Wójcik-Superczyńska M, Głogowski M, Barinow-Wojewódzki A, Milanowski J, Krzakowski M.

Oncol Lett. 2017 Jun;13(6):4433-4444. doi: 10.3892/ol.2017.5980. Epub 2017 Apr 3.

7.

Diagnostic and therapeutic guidelines for gastro-entero-pancreatic neuroendocrine neoplasms (recommended by the Polish Network of Neuroendocrine Tumours).

Kos-Kudła B, Blicharz-Dorniak J, Strzelczyk J, Bałdys-Waligórska A, Bednarczuk T, Bolanowski M, Boratyn-Nowicka A, Borowska M, Cichocki A, Ćwikła JB, Falconi M, Foltyn W, Handkiewicz-Junak D, Hubalewska-Dydejczyk A, Jarząb B, Junik R, Kajdaniuk D, Kamiński G, Kolasińska-Ćwikła A, Kowalska A, Król R, Królicki L, Krzakowski M, Kunikowska J, Kuśnierz K, Lampe P, Lange D, Lewczuk-Myślicka A, Lewiński A, Lipiński M, Londzin-Olesik M, Marek B, Nasierowska-Guttmejer A, Nawrocki S, Nowakowska-Duława E, Pilch-Kowalczyk J, Rosiek V, Ruchała M, Siemińska L, Sowa-Staszczak A, Starzyńska T, Steinhof-Radwańska K, Sworczak K, Syrenicz A, Szawłowski A, Szczepkowski M, Wachuła E, Zajęcki W, Zemczak A, Zgliczyński W, Zieniewicz K.

Endokrynol Pol. 2017;68(2):79-110. doi: 10.5603/EP.2017.0015.

8.

Pathophysiology and clinical characteristics of pain in most common locations in cancer patients.

Leppert W, Zajaczkowska R, Wordliczek J, Dobrogowski J, Woron J, Krzakowski M.

J Physiol Pharmacol. 2016 Dec;67(6):787-799.

9.

[Liposomal doxorubicin in patients with breast cancer and concomitant cardiovascular diseases - interdisciplinary expert opinion].

Szmit S, Filipiak KJ, Litwiniuk M, Opolski G, Wysocki P, Zaborska B, Krzakowski M.

Kardiol Pol. 2016;74(9):1031-6. doi: 10.5603/KP.2016.0127. Polish.

PMID:
27654476
10.

A decrease in D-dimer concentration and an occurrence of skin rash as iatrogenic events and complementary predictors of survival in lung cancer patients treated with EGFR tyrosine kinase inhibitors.

Zaborowska-Szmit M, Kowalski DM, Piórek A, Krzakowski M, Szmit S.

Pharmacol Rep. 2016 Dec;68(6):1140-1148. doi: 10.1016/j.pharep.2016.07.003. Epub 2016 Jul 20.

PMID:
27588390
11.

The Effectiveness of Pemetrexed Monotherapy Depending on Polymorphisms in TS and MTHFR Genes as Well as Clinical Factors in Advanced NSCLC Patients.

Kucharczyk T, Krawczyk P, Powrózek T, Kowalski DM, Ramlau R, Kalinka-Warzocha E, Knetki-Wróblewska M, Winiarczyk K, Krzakowski M, Milanowski J.

Pathol Oncol Res. 2016 Jan;22(1):49-56. doi: 10.1007/s12253-015-9966-z. Epub 2015 Aug 16.

12.

Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO).

Vansteenkiste J, Barlesi F, Waller CF, Bennouna J, Gridelli C, Goekkurt E, Verhoeven D, Szczesna A, Feurer M, Milanowski J, Germonpre P, Lena H, Atanackovic D, Krzakowski M, Hicking C, Straub J, Picard M, Schuette W, O'Byrne K.

Ann Oncol. 2015 Aug;26(8):1734-40. doi: 10.1093/annonc/mdv219. Epub 2015 May 4.

PMID:
25939894
13.

Analysis of patient-reported outcomes from the LUME-Lung 1 trial: a randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer.

Novello S, Kaiser R, Mellemgaard A, Douillard JY, Orlov S, Krzakowski M, von Pawel J, Gottfried M, Bondarenko I, Liao M, Barrueco J, Gaschler-Markefski B, Griebsch I, Palmer M, Reck M; LUME-Lung 1 Study Group.

Eur J Cancer. 2015 Feb;51(3):317-26. doi: 10.1016/j.ejca.2014.11.015. Epub 2014 Dec 17.

14.

Correlation between TS, MTHFR, and ERCC1 gene polymorphisms and the efficacy of platinum in combination with pemetrexed first-line chemotherapy in mesothelioma patients.

Powrózek T, Kowalski DM, Krawczyk P, Ramlau R, Kucharczyk T, Kalinka-Warzocha E, Knetki-Wróblewska M, Winiarczyk K, Dyszkiewicz W, Krzakowski M, Milanowski J.

Clin Lung Cancer. 2014 Nov;15(6):455-65. doi: 10.1016/j.cllc.2014.06.009. Epub 2014 Aug 15.

PMID:
25246386
15.

Methodological recommendations for the diagnostics of EGFR gene mutations and ALK gene rearrangement in the selection of non-small-cell lung cancer patients to molecularly targeted therapies.

Krawczyk P, Chorostowska-Wynimko J, Dziadziuszko R, Jassem J, Krzakowski M, Langfort R, Puacz E, Wasąg B, Wojas-Krawczyk K.

Pneumonol Alergol Pol. 2014;82(5):437-44. doi: 10.5603/PiAP.2014.0057.

16.

The efficacy of EGFR gene mutation testing in various samples from non-small cell lung cancer patients: a multicenter retrospective study.

Krawczyk P, Ramlau R, Chorostowska-Wynimko J, Powrózek T, Lewandowska MA, Limon J, Wasąg B, Pankowski J, Kozielski J, Kalinka-Warzocha E, Szczęsna A, Wojas-Krawczyk K, Skroński M, Dziadziuszko R, Jaguś P, Antoszewska E, Szumiło J, Jarosz B, Woźniak A, Jóźwicki W, Dyszkiewicz W, Pasieka-Lis M, Kowalski DM, Krzakowski M, Jassem J, Milanowski J.

J Cancer Res Clin Oncol. 2015 Jan;141(1):61-8. doi: 10.1007/s00432-014-1789-x. Epub 2014 Aug 3.

17.

Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients.

Krawczyk P, Kucharczyk T, Kowalski DM, Powrózek T, Ramlau R, Kalinka-Warzocha E, Winiarczyk K, Knetki-Wróblewska M, Wojas-Krawczyk K, Kałakucka K, Dyszkiewicz W, Krzakowski M, Milanowski J.

J Cancer Res Clin Oncol. 2014 Dec;140(12):2047-57. doi: 10.1007/s00432-014-1756-6. Epub 2014 Jul 16.

18.

[Role of echocardiography in monitoring of cardiac toxicity of cancer pharmacotherapy. Expert consensus statement of the Polish Clinical Forum for Cardiovascular Imaging].

Piotrowski G, Gawor R, Gawor Z, Szmit S, Kasprzak JD, Miśkiewicz Z, Opolski G, Torbicki A, Krzakowski M, Filipiak KJ, Szyszka A, Płońska-Gościniak E; Polskie Kliniczne Forum Obrazowania Serca i Naczyń.

Kardiol Pol. 2014;72(6):558-75. doi: 10.5603/KP.2014.0126. Polish.

PMID:
24961458
19.
20.

Oral vinorelbine plus cisplatin as first-line chemotherapy in nonsquamous non-small-cell lung cancer: final results of an International randomized phase II study (NAVotrial 01).

Bennouna J, Havel L, Krzakowski M, Kollmeier J, Gervais R, Dansin E, Serke M, Favaretto A, Szczesna A, Cobo M, Ciuffreda L, Jassem J, Nicolini M, Ramlau R, Amoroso D, Melotti B, Almodovar T, Riggi M, Caux NR, Vaissière N, Tan EH.

Clin Lung Cancer. 2014 Jul;15(4):258-65. doi: 10.1016/j.cllc.2014.04.007. Epub 2014 May 15.

PMID:
24954228

Supplemental Content

Loading ...
Support Center